The abstract is read at the publisher; the summary is JClub's.
Caenorhabditis elegans with lin-45(V627E) shows high-dose trametinib resistance, and increased egl-30 expression links to Gαq-PLC-PKC signaling in this phenotype.
- Why it matters: Resistance to MEK inhibitors like trametinib limits durable benefit, and the mechanisms that keep MAPK activity during treatment are not well defined.
- What they did: The authors built a lin-45(V627E) model, used transcriptomics to find egl-30 upregulation under high-dose trametinib, and tested EGL-30/Gαq-PLC-PKC via genetic and pharmacological perturbations; they then examined PAR2 (F2RL1) in trametinib-resistant A375 cells and inhibited PAR2 or Gαq signaling.
- The result: In resistant melanoma cells, blocking PAR2 or downstream Gαq signaling reduced ERK phosphorylation and impaired viability, and combined MEK plus Gαq-PLC-PKC inhibition synergistically suppressed xenograft growth and restored trametinib sensitivity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.